KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Taxes: 2010-2025

Historic Change in Taxes for Emergent BioSolutions (EBS) over the last 12 years, with Sep 2025 value amounting to $6.2 million.

  • Emergent BioSolutions' Change in Taxes fell 40.95% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 134.21%. This contributed to the annual value of $23.3 million for FY2024, which is 243.83% up from last year.
  • As of Q3 2025, Emergent BioSolutions' Change in Taxes stood at $6.2 million, which was down 8.82% from $6.8 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Change in Taxes peaked at $79.7 million during Q4 2022, and registered a low of -$40.9 million during Q2 2022.
  • Over the past 3 years, Emergent BioSolutions' median Change in Taxes value was $3.8 million (recorded in 2023), while the average stood at $1.2 million.
  • Within the past 5 years, the most significant YoY rise in Emergent BioSolutions' Change in Taxes was 334.55% (2023), while the steepest drop was 284.78% (2023).
  • Quarterly analysis of 4 years shows Emergent BioSolutions' Change in Taxes stood at $79.7 million in 2022, then crashed by 115.93% to -$12.7 million in 2023, then soared by 74.02% to -$3.3 million in 2024, then slumped by 40.95% to $6.2 million in 2025.
  • Its Change in Taxes was $6.2 million in Q3 2025, compared to $6.8 million in Q2 2025 and -$8.4 million in Q1 2025.